Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CET
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
03/23 ONCOLYTICS BIOTECH : reg; Inc. Enters into First-in-Class Collaboration with Mye..
03/22 Cigna Named i4cp's Member of the Year
03/22 CELGENE : House Oversight and Government Reform Subcommittee on Health Care, Ben..
03/16 CELGENE : Oral OTEZLA® Apremilast Demonstrated Significant Improvement versus Pl..
03/15 ALLIQUA BIOMEDICAL, INC. (NASDAQ : ALQA) Files An 8-K Entry into a Material Defi..
03/14 AGIOS PHARMACEUTICALS : Announces MTAP Pathway Research Program as Development P..
03/14 CELGENE : embraces MTAP cancer deal with fast-moving collaborator Agios
03/13 AGIOS PHARMACEUTICALS, INC. (NASDAQ : AGIO) Files An 8-K Other Events
03/11 CELGENE : Regenacy Pharmaceuticals Demonstrates Reversal Of Chemotherapy-Induced..
03/09 Genentech & Bristol-Myers Squibb Dominate Franchise Image, Overall Engagement..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/20 Corporate Venture Capital - Savior Of Medtech?
03/20 Novo Nordisk - Another Apple 2013 Story? New Highs Ahead?
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/16 CELGENE : In Breakout Mode?
Advertisement
Financials ($)
Sales 2017 13 286 M
EBIT 2017 7 280 M
Net income 2017 4 542 M
Debt 2017 3 113 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 17,66
EV / Sales 2017 7,45x
EV / Sales 2018 6,28x
Capitalization 95 861 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 141 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION6.45%95 861
AMGEN, INC.13.56%122 281
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
ACTELION LTD24.72%29 697
VERTEX PHARMACEUTICALS..20.88%22 123
More Results